Success Metrics

Clinical Success Rate
75.4%

Based on 46 completed trials

Completion Rate
75%(46/61)
Active Trials
2(3%)
Results Posted
48%(22 trials)
Terminated
15(21%)

Phase Distribution

Ph phase_1
15
21%
Ph phase_3
1
1%
Ph phase_2
24
33%
Ph early_phase_1
3
4%
Ph not_applicable
26
36%

Phase Distribution

18

Early Stage

24

Mid Stage

1

Late Stage

Phase Distribution69 total trials
Early Phase 1First-in-human
3(4.3%)
Phase 1Safety & dosage
15(21.7%)
Phase 2Efficacy & side effects
24(34.8%)
Phase 3Large-scale testing
1(1.4%)
N/ANon-phased studies
26(37.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

70.8%

46 of 65 finished

Non-Completion Rate

29.2%

19 ended early

Currently Active

2

trials recruiting

Total Trials

73

all time

Status Distribution
Active(2)
Completed(46)
Terminated(19)
Other(6)

Detailed Status

Completed46
Terminated15
unknown6
Withdrawn4
Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials
73
Active
2
Success Rate
75.4%
Most Advanced
Phase 3

Trials by Phase

Early Phase 13 (4.3%)
Phase 115 (21.7%)
Phase 224 (34.8%)
Phase 31 (1.4%)
N/A26 (37.7%)

Trials by Status

withdrawn45%
terminated1521%
unknown68%
active_not_recruiting23%
completed4663%

Recent Activity

2 active trials
Showing 5 of 73
active_not_recruitingnot_applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT02226276
active_not_recruitingphase_2

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

NCT01697527
completedphase_2

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

NCT01359592
completednot_applicable

PET Scan in Treating Patients With Metastatic Prostate Cancer

NCT00002981
terminatednot_applicable

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

NCT01931709
View all 73 trials

Clinical Trials (73)

Showing 20 of 73 trialsScroll for more
NCT02226276Not Applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Active Not Recruiting
NCT01697527Phase 2

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active Not Recruiting
NCT01359592Phase 2

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Completed
NCT00002981Not Applicable

PET Scan in Treating Patients With Metastatic Prostate Cancer

Completed
NCT01931709Not Applicable

FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer

Terminated
NCT00346125Not Applicable

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Completed
NCT01462630Phase 2

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Completed
NCT00978874Not Applicable

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

Terminated
NCT01807117Not Applicable

PET-MRI in Diagnosing Patients With Colon or Rectal Cancer

Completed
NCT00983697Not Applicable

FDG-PET/CT in Assessing the Tumor and Planning Neck Surgery in Patients With Newly Diagnosed H&N Cancer

Unknown
NCT00450567

Glucose Metabolism in Patients With Non-Small Cell Lung Cancer Treated With Targeted Therapy and Chemotherapy

Completed
NCT00433459Phase 3

Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Completed
NCT02287636Not Applicable

PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer

Completed
NCT00602043Phase 2

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

Completed
NCT01476410Phase 2

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Unknown
NCT01720602Not Applicable

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Completed
NCT00416455Phase 1

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

Completed
NCT02891616Phase 1

18F-FLT PET Imaging in Patients With Advanced Melanoma

Terminated
NCT01537107Phase 1

Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

Completed
NCT02717572Phase 1

18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR

Completed

Drug Details

Intervention Type
RADIATION
Total Trials
73